Atlas FDA

Orsiro Mission Sirolimus Eluting Coronary Stent System

FDA premarket approval P170030/S028 · decided 2023-12-21

Approval details

PMA number
P170030
Supplement
S028
Supplement type
Normal 180 Day Track
Supplement reason
Labeling Change - Indications/instructions/shelf life/tradename
Trade name
Orsiro Mission Sirolimus Eluting Coronary Stent System
Generic name
Coronary drug-eluting stent
Applicant
Biotronik AG
Date received
2023-03-31
Decision date
2023-12-21
Days to decision
265 days
Decision code
APPR
Product code
NIQ
Advisory committee
Cardiovascular
Expedited review
No
Location
Bülach
Statement
approval for an update to the specification for the maximum post-dilatation diameter for the T6S stent design from 3.5 mm to 4.0 mm

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
PHERON PERIPHERAL PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY (PTA) CATHETER (K052757)Biotronik AG2005-10-28